Media about us

• Blood Test Offers An Amazing View Of Metastatic Prostate Cancer Cells

  04 February 2016 Elaine Schattner / Forbes

  

  A few months ago, I met with Murali Prahalad, CEO of Epic Sciences (San Diego). We discussed the company’s methods of processing blood samples to store, identify and examine circulating tumor cells (CTCs). Since then I’ve been following reports on Epic’s method and other, competing CTC platforms.

• Biomarker Discovery Gets a Fix on Cancer

  01 February 2016 Cancer Kathy Liszewski / Genetic Engineering & Biotechnology News

  

  ust as signposts provide information, direction, and guidance, so too cancer biomarkers can better reveal the complex, dynamic, and heterogeneous landscape of malignancies. Such information is critical for creating better cancer diagnostics, prognostics, and therapeutics, but the journey to find just the right biomarker is often a long and winding road.

• Subscribe to Cancer Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

  28 January 2016 GenomeWeb

  

  Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

• Epic Sciences, Station X Link Up to Analyze CTC Data for CDx Development

  25 January 2016 GenomeWeb

  

  Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.

• Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration

  22 January 2016 Business Wire

  

  Georgia Bio announced its 2016 Deals of the Year for pharmaceutical, biotechnology, healthcare IT and medical device companies in the following categories – private financing, joint ventures, initial public offering, mergers, acquisitions and economic development – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions by life sciences companies in Georgia such as financings, partnering agreements and government grants that are significant to the state’s industry development.

• Never leave a cell behind

  20 January 2016 Lori Lesko / Cancer Research News, DDNews

  

  Targeted toward cracking the code to treating disease resistance in tumor changes, Epic Sciences Inc. has partnered with the Penn Medicine Abramson Cancer Center on multiple studies to explore biomarkers, identified by the analysis of circulating tumor cells (CTCs) at a single-cell resolution. This process is predictive of response to personalized cancer therapeutics—and a precursor to the future of oncology.

• Companion Diagnostics Evolve

  19 January 2016 Chelsea Lacey-Mabe / Advanced healthcare Network

  

  Out of seven billion people on this earth, no two people are the same. Companion diagnostics (CDx) providers argue their medicines shouldn't be the same either. In a world where someone can customize their sandwich, sneakers and even their physical appearance, the healthcare industry has realized one-size-fits-all treatments are no longer a good fit.

• Breast cancer biotech Syndax Pharmaceuticals refiles for an $86 million IPO

  04 January 2016 Renaissance Capital IPO Center

  

  Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled on Monday with the SEC to raise up to $86 million in an initial public offering.

• Marinus Pharmaceuticals Completes Enrollment in Phase 3 Trial For Ganaxolone Anti-Seizure Treatment

  18 December 2015 The Stock Informant

  

  Marinus Pharmaceuticals (NASDAQ:MRNS), which focuses on the development of treatments for epilepsy and neuropsychiatric disorders, said it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures.

• NovaMedica to invest $15 million in new R&D centre

  18 December 2015 CeSports.EU

  

  The Russian pharmaceutical company, NovaMedica, has announced plans to build a new research and development centre at Technopolis Moscow.  The new site will include laboratories with brand new state-of-the-art equipment and will allow the company to run up to fifteen projects each year and means that they will be able to produce approximately 75 million doses per year thanks to the production areas.